S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Sponsor: Eastern Cooperative Oncology Group
Listed as NCT00003590, this PHASE2 trial focuses on Adult Meningioma and remains completed. Sponsored by Eastern Cooperative Oncology Group, it has been updated 9 times since 1998, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2021 — May 2023 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Nov 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .